Seamus Sustani: We're building a human-centric platform that is going to help people achieve these amazing health outcomes. Cara, one of the studies that I looked at before joining Weight Watchers was Dan Butner's research on blue zones and where he has looked at the places in the world where people live to be 100 centenarians. And it's not just how they move or what they eat, both of which we address through our food algorithm and our program. It's the social circles. The community. What I'm doing here right now is building us out into a third space, a digital first era.
WeightWatchers recently announced a $132 million deal to acquire telehealth company Sequence and enter the prescription drug space (think: GLP-1 drugs like Wegovy and Ozempic). It begs the question: why is a company built on personal accountability facilitating medical interventions? We ask our guest, WeightWatchers CEO Sima Sistani. Before and after the interview, Nayeema and Kara discuss their own experiences with diet fads and whether drugs like Wegovy and Ozempic will help America deal with the obesity epidemic or simply avoid tackling underlying issues like food supply, corporate greed and light regulation.
Questions? Comments? Email us at on@voxmedia.com or find us on Twitter @karaswisher and @nayeema
Learn more about your ad choices. Visit podcastchoices.com/adchoices